Top Markets
Coin of the day
Nabriva Therapeutics plc Nabriva Therapeutics plc

Nabriva Therapeutics plc

NBRV
Hisse Senetlerindeki Sıralama #39979
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
Hisse Fiyatı
$0.63
Son senkronizasyon: 2023-08-29
Piyasa Değeri
$284.20K
Değişim (1 gün)
-21.25%
Değişim (1 yıl)
0.00%
Ülke
IE
Ticaret Nabriva Therapeutics plc (NBRV)

Kategori

Nabriva Therapeutics plc (NBRV) için temettü verimi geçmişi
Nabriva Therapeutics plc (hisse sembolü: NBRV) temettü verimi (TTM) 2026 itibariyle: 0
Son 5 yılın ortalama temettü verimi: 0.00%
Nabriva Therapeutics plc (NBRV) için 2026 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
Yıl Temettü Verimi Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin temettü verimi (TTM)